Business Development

Strategy

ACUTE HOSPITAL CARE
The Medicines Company specializes in acute care hospital products. We acquire, develop and commercialize pharmaceutical products in late stages of their development. We focus our commercial and product development resources primarily on the U.S. hospital market.

Development And Commercial Capabilities

We acquired rights to Angiomax, clevidipine and cangrelor to establish our current acute franchise. We exclusively licensed Angiomax from Biogen (a predecessor of Biogen Idec, Inc.) in 1997. We acquired clevidipine in March 2003 and cangrelor in December 2003 from AstraZeneca AB.

We add value to licensed products by employing a focused approach to late-stage product development. We have a track record of conducting innovative clinical trial programs and applying novel manufacturing development expertise. We have completed more than 25 clinical trials and have enrolled more than 40,000 patients in our trials to-date.

We believe more than 1 million patients have benefited from Angiomax therapy since its launch in 2001. Angiomax net revenues in 2004 were $144.3 million. The product is supported by a hospital sales force of 139 sales representatives and managers.

As a result of our experience commercializing Angiomax, we have developed in-depth know-how related to the practice of acute hospital care and gained valuable insights into procurement processes, usage patterns, caregiver preferences and the evaluation of products by our hospital customers.